APA (7th ed.) Citation

Hsieh, S., Liu, W., Huang, Y., Lin, Y., Hsieh, E., Lian, W., . . . Chang, S. (2021). Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. EClinicalMedicine, 38, 100989. https://doi.org/10.1016/j.eclinm.2021.100989

Chicago Style (17th ed.) Citation

Hsieh, Szu-Min, et al. "Safety and Immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in Healthy Adults: A Phase 1, Dose-escalation Study." EClinicalMedicine 38 (2021): 100989. https://doi.org/10.1016/j.eclinm.2021.100989.

MLA (9th ed.) Citation

Hsieh, Szu-Min, et al. "Safety and Immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVCCOV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in Healthy Adults: A Phase 1, Dose-escalation Study." EClinicalMedicine, vol. 38, 2021, p. 100989, https://doi.org/10.1016/j.eclinm.2021.100989.